BA BA - Hemostemix President, CoFounder

HEM Stock

CAD 0.08 0.01 5.88%

Insider

BA BA is President, CoFounder of Hemostemix

Age	62
Address	707-7th Avenue SW, Calgary, AB, Canada, T2P 3H6
Phone	905-580-4170
Web	https://hemostemix.com

Hemostemix Management Efficiency

The company has return on total asset (ROA) of (3.4924) % which means that it has lost $3.4924 on every $100 spent on assets. This is way below average. Hemostemix's management efficiency ratios could be used to measure how well Hemostemix manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Hemostemix's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.36 in 2024, whereas Return On Tangible Assets are likely to drop (8.37) in 2024. Debt To Assets is likely to climb to 14.46 in 2024, whereas Total Assets are likely to drop slightly above 298.1 K in 2024.

Compare Hemostemix to Peers

Predict price of Hemostemix

Hemostemix has accumulated 4.32 M in total debt. Hemostemix has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Hemostemix until it has trouble settling it off, either with new capital or with free cash flow. So, Hemostemix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hemostemix sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hemostemix to invest in growth at high rates of return. When we think about Hemostemix's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 6 records			INSIDER Age
	Jim Graba	VentriPoint Diagnostics	N/A
	Jessica Naman	VentriPoint Diagnostics	N/A
	CPA CMA	VentriPoint Diagnostics	54
	Hirotaka Katagiri	VentriPoint Diagnostics	N/A
	BASc ICDD	VentriPoint Diagnostics	70
	Desmond Hirson	VentriPoint Diagnostics	N/A

Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. HEMOSTEMIX INC is traded on TSX Venture Exchange in Canada. Hemostemix (HEM) is traded on TSX Venture Exchange in Canada and employs 6 people. Hemostemix is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Asset

-3.49

Hemostemix Leadership Team

Elected by the shareholders, the Hemostemix's board of directors comprises two types of representatives: Hemostemix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hemostemix. The board's role is to monitor Hemostemix's management team and ensure that shareholders' interests are well served. Hemostemix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hemostemix's outside directors are responsible for providing unbiased perspectives on the board's policies.

	BA BA, President, CoFounder
	MD Sr, Chief Officer
	Thomas CA, Pres Inc
	Peter Pavlin, Vice Operations
	Cameron Cole, Head Relations
	Christina CPA, Interim Officer

Hemostemix Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hemostemix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Number Of Shares Shorted

451

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Hemostemix Stock Analysis

When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC